ELSEVIER

Journal of Neurological Sciences 150 (1997) 185–186

JOURNAL OF THE
NEUROLOGICAL
SCIENCES

Author Index Volume 150

Abe, K., see Shizuka, M. (150) 133
Albers, J.W., see Bromberg, M.B. (150) 59
Algra, A., see Rosendaal, F.R. (150) 85
Ando, M., see Nakamura, M. (150) 161
Aoki, M., see Shizuka, M. (150) 133
Arenas, J., see Molina, J.A. (150) 123
Ariga, T., see Yuki, N. (150) 81
Augustin, M., see Horner, S. (150) 49

Barreira, A.A., see Flores-Vieira, C.L.L. (150) 3
Barreira, A.A., see Flores-Vieira, C.L.L. (150) 13
Benito-León, J., see Molina, J.A. (150) 123
Bermejo, F., see Molina, J.A. (150) 123
Berrouschot, J., Rolle, K., Kühn, H.-J. and Schneider, D.
Serum neuron-specific enolase levels do not increase after electroconvulsive therapy (150) 173
Bosone, D., see Micieli, G. (150) 71
Bromberg, M.B., Wald, J.J., Forshew, D.A., Feldman, E.L. and Albers, J.W.
Randomized trial of azathioprine or prednisone for initial immunosuppressive treatment of myasthenia gravis (150) 59

Casademont, J., see Miró, Ò. (150) 153
Cavallini, A., see Micieli, G. (150) 71
Cebrián, M., see Miró, Ò. (150) 153
Chimelli, L., see Flores-Vieira, C.L.L. (150) 13
Cho, S.J., Sohn, Y.H., Kim, G.W. and Kim, J.-S.
Blood flow velocity changes in the middle cerebral artery as an index of the chronicity of hypertension (150) 77
Chopp, M., see Li, Y. (150) 93
Christopher, R., see Nagaraja, D. (150) 137
Costa, A., see Micieli, G. (150) 71

Date, Y., Nakazato, M., Kangawa, K., Shirieda, K., Fujimoto, T. and Matsukura, S.
Detection of three transthyretin gene mutations in familial amyloidotic polyneuropathy by analysis of DNA extracted from formalin-fixed and paraffin-embedded tissues (150) 143
Diener, H.C. and Lowenthal, A.
Reply to Rosendaal and Algra regarding recalculation of ESPS 2 results including data of all patients originating from one centre (150) 87
Duft, M., see Horner, S. (150) 49

Egger, M., see Wilder-Smith, E. (150) 33

Feldman, E.L., see Bromberg, M.B. (150) 59
Fernandes, R.M.F., see Flores-Vieira, C.L.L. (150) 13
Flores-Vieira, C.L.L. and Barreira, A.A.
Experimental benznidazole encephalopathy. I. Clinical-neurological alterations (150) 3
Flores-Vieira, C.L.L., Chimelli, L., Fernandes, R.M.F. and Barreira, A.A.
Experimental benznidazole encephalopathy: II. Electroencephalographic and morphological alterations (150) 13
Forshew, D.A., see Bromberg, M.B. (150) 59
Fujimoto, T., see Date, Y. (150) 143

Gasalla, T., see Molina, J.A. (150) 123
Gómez, P., see Molina, J.A. (150) 123
Gourie-Devi, M., Nalini, A. and Subbakrishna, D.K.
Temporary amelioration of symptoms with intravenous cyclophosphamide in amyotrophic lateral sclerosis (150) 167
Grau, J.M., see Miró, Ò. (150) 153

Harb, S., see Horner, S. (150) 49
Horner, S., Ni, X.S., Weihs, W., Harb, S., Augustin, M., Duft, M. and Niederkorn, K.
Simultaneous bilateral contrast transcranial doppler monitoring in patients with intracardiac and intrapulmonary shunts (150) 49
Hunter, S.F., Miller, D.J. and Rodriguez, M.
Monoclonal remyelination-promoting natural autoantibody SCH 94.03: pharmacokinetics and in vivo targets within demyelinated spinal cord in a mouse model of multiple sclerosis (150) 103
Hyslop, T., see Schwartzman, R.J. (150) 149

Ikeda, Y., see Shizuka, M. (150) 133
Itoyama, Y., see Shizuka, M. (150) 133

Jiménez-Jiménez, F.J., see Molina, J.A. (150) 123

Kangawa, K., see Date, Y. (150) 143
Kim, G.W., see Cho, S.J. (150) 77
Kim, J.-S., see Cho, S.J. (150) 77
Kodama, N., see Okuda, B. (150) 129
Kühn, H.-J., see Berrouschot, J. (150) 173
Kuo, M.-F., see Tu, Y.-K. (150) 115

Lanska, D.J.
The geographic distribution of Parkinson's disease mortality in the United States (150) 63
Li, Y., Chopp, M. and Powers, C.
Granule cell apoptosis and protein expression in hippocampal dentate gyrus after forebrain ischemia in the rat (150) 93
Liu, H.-M., see Tu, Y.-K. (150) 115
Liu, J.E., see Schwartzman, R.J. (150) 149
Lowenthal, A., see Diener, H.C. (150) 87

Mallolas, J., see Miró, Ò. (150) 153
Manjari, T., see Nagaraja, D. (150) 137
Marcheselli, S., see Micieli, G. (150) 71
Masanés, F., see Miró, Ò. (150) 153
Matsukura, S., see Date, Y. (150) 143
Matuura, T., see Nakamura, M. (150) 161
Micieli, G., Bosone, D., Costa, A., Cavallini, A., Marcheselli, S., Pompeo, F. and Nappi, G.

Opposite effects of L-arginine and nitroglycerin on cerebral blood velocity: Nitric oxide precursors and cerebral blood velocity (150) 71
Miller, D.J., see Hunter, S.F. (150) 103
Miró, Ò., Pedrol, E., Cebrián, M., Masanés, F., Casademont, J., Mallolas, J. and Grau, J.M.
Skeletal muscle studies in patients with HIV-related wasting syndrome (150) 153
Mita, S., see Nakamura, M. (150) 161
Mizushima, K., see Shizuka, M. (150) 133
Molina, J.A., Jiménez-Jiménez, F.J., Gómez, P., Vargas, C., Navarro, J.A., Ortí-Pareja, M., Gasalla, T., Benito-León, J., Bermejo, F. and Arenas, J.
Decreased cerebrospinal fluid levels of neutral and basic amino acids in patients with Parkinson's disease (150) 123

Nagaraja, D., Christopher, R. and Manjari, T.
Anticardiolipin antibodies in ischemic stroke in the young: Indian experience (150) 137
Nagashima, K., see Nakamura, M. (150) 161
Nakamura, M., Mita, S., Matuura, T., Nagashima, K., Tanaka, H., Ando, M. and Uchino, M.
The reduction of androgen receptor mRNA in motoneurons of X-linked spinal and bulbar muscular atrophy (150) 161
Nakazato, M., see Date, Y. (150) 143
Nalini, A., see Gourie-Devi, M. (150) 167
Nappi, G., see Micieli, G. (150) 71
Navarro, J.A., see Molina, J.A. (150) 123
Netzer, J., see Pfeiffer, G. (150) 39
Ni, X.S., see Horner, S. (150) 49
Niederkorn, K., see Horner, S. (150) 49
Nighoghossian, N. and Trouillas, P.
Hyperbaric oxygen in the treatment of acute ischemic stroke: an unsettled issue (150) 27

Okamoto, K., see Shizuka, M. (150) 133
Okuda, B., Kodama, N., Tachibana, H. and Sugita, M.
Motor neuron disease following generalized fasciculations and cramps (150) 129
Ortí-Pareja, M., see Molina, J.A. (150) 123

Pedrol, E., see Miró, Ò. (150) 153
Pfeiffer, G. and Netzer, J.
Spectral analysis of heart rate and blood pressure in Guillain-Barré patients with respiratory failure (150) 39
Pompeo, F., see Micieli, G. (150) 71
Powers, C., see Li, Y. (150) 93
Rodriguez, M., see Hunter, S.F. (150) 103
Rolle, K., see Berrouschot, J. (150) 173
Rosendaal, F.R. and Algra, A.
Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke (150) 85

Schneider, D., see Berrouschot, J. (150) 173
Schwartzman, R.J., Liu, J.E., Smullens, S.N., Hyslop, T. and Tahmoush, A.J.
Long-term outcome following sympathectomy for complex regional pain syndrome type 1 (RSD) (150) 149
Shirieda, K., see Date, Y. (150) 143
Shizuka, M., Watanabe, M., Aoki, M., Ikeda, Y., Mizushima, K., Okamoto, K., Itoyama, Y., Abe, K. and Shoji, M.
Analysis of the McLeod syndrome gene in three patients with neuroacanthocytosis (150) 133
Shoji, M., see Shizuka, M. (150) 133
Smullens, S.N., see Schwartzman, R.J. (150) 149
Sohn, Y.H., see Cho, S.J. (150) 77
Subbakrishna, D.K., see Gourie-Devi, M. (150) 167
Sugita, M., see Okuda, B. (150) 129

Tachibana, H., see Okuda, B. (150) 129
Tahmoush, A.J., see Schwartzman, R.J. (150) 149
Tanaka, H., see Nakamura, M. (150) 161
Trouillas, P., see Nighoghossian, N. (150) 27
Tu, Y.-K., Kuo, M.-F. and Liu, H.-M.
Cerebral oxygen transport and metabolism during graded isovolemic hemodilution in experimental global ischemia (150) 115

Uchino, M., see Nakamura, M. (150) 161

Vargas, C., see Molina, J.A. (150) 123

Wald, J.J., see Bromberg, M.B. (150) 59
Watanabe, M., see Shizuka, M. (150) 133
Weihs, W., see Horner, S. (150) 49
Wilder-Smith, A., see Wilder-Smith, E. (150) 33
Wilder-Smith, E., Wilder-Smith, A. and Egger, M.
Peripheral autonomic nerve dysfunction in asymptomatic leprosy contacts (150) 33

Yuki, N. and Ariga, T.
Antibodies to fucogangliosides in neurological diseases (150) 81

ELSEVIER

Journal of Neurological Sciences 150 (1997) 187–188

JOURNAL OF THE
NEUROLOGICAL
SCIENCES

Subject Index Volume 150

AIDS (150) 153
Allodynia (150) 149
Amyotrophic lateral sclerosis (150) 129
Amyotrophic lateral sclerosis-treatment-cyclophosphamide (150) 167
Androgen receptor (150) 161
Anticardiolipin antibodies (150) 137
Apoptosis (150) 93
L-arginine (150) 71
Artificial ventilation (150) 39
Autoantibody (150) 81
Autonomic nerve damage (150) 33
Azathioprine (150) 59

Basic amino acids (150) 123
Benznidazole (150) 3, (150) 13
Blood flow velocity (150) 77
Brain injury (150) 173

Cardiovascular monitoring (150) 39
Cerebral blood flow (150) 115
Cerebral blood velocity (150) 71
Cerebral oxygen metabolism (150) 115
Cerebral oxygen transport (150) 115
Cerebrospinal fluid (150) 123
Cerebrovascular disorders (150) 77
Chagas' disease (150) 3, (150) 13
Clinical-neurological alterations (150) 3
Complex regional pain syndrome (150) 149
Contrast transcranial Doppler sonography (150) 49
Corticosteroids (150) 59
Cramp (150) 129
Cyclin protein (150) 93

Demography (150) 63
Demyelination (150) 103
DNA sequencing (150) 143

Early leprosy neuropathy (150) 33
Echocardiography (150) 49
Efficiency (150) 27
Electroconvulsive therapy (150) 173
Electroencephalographic and morphological alterations (150) 13
Embolism (150) 49
Epidemiology (150) 63
Experimental encephalopathy (150) 3, (150) 13

Familial amyloidotic polyneuropathy (150) 143
Fasciculation (150) 129
Forebrain ischemia (150) 93
Formalin-fixed and paraffin-embedded tissues (150) 143
Fucoganglioside (150) 81
Fucosyl-GM1 (150) 81

Geography (150) 63
Global cerebral ischemia (150) 115
Guillain-Barré syndrome (150) 39

Heart rate variability (150) 39
HIV (150) 153
Hyperalgesia (150) 149
Hyperbaric oxygen (150) 27
Hyperpathia (150) 149
Hypertension (150) 77

Immunosuppression (150) 59
In situ hybridization (150) 161
Intrapulmonary shunt (150) 49
Ischemic stroke (150) 27
Isovolemic hemodilution (150) 115

Leprosy contacts (150) 33

Major depressive disorder (150) 173
Maps (150) 63
McLeod syndrome (150) 133
Motoneuron (150) 161
Motor neuron disease (150) 129
Multiple sclerosis (150) 103
Muscle biopsy (150) 153
Muscle histology (150) 153
Myasthenia gravis (150) 59
Myelin (150) 103

Natural autoantibody (150) 103
Neuroacanthocytosis (150) 133
Neuron-specific enolase (150) 173
Neutral amino acids (150) 123
Nitric oxide (150) 71
Nitroglycerin (150) 71

Oligodendrocyte (150) 103
Oxygen extraction fraction (150) 115

p53 response proteins (150) 93
Parkinson's disease (150) 63, (150) 123
Patent foramen ovale (150) 49
PCR-IMRA (150) 143
PCR-RFLP (150) 143
Pharmacokinetics (150) 103
Plasma (150) 123
Prednisone (150) 59
Prothrombotic state (150) 137
Pulsatility index (150) 77

Rat (150) 93
Reflex sympathetic dystrophy (150) 149
Remyelination (150) 103
Risk factors (150) 63

Sensory neuropathy (150) 81
Spectral analysis (150) 39
Statistics (150) 63
Stroke (150) 49
Stroke in the young (150) 137
Sympathectomy (150) 149
Sympathetic blockade (150) 149

Theiler's virus (150) 103
Transcranial Dopplersonography (150) 71
Transcranial Doppler ultrasonography (150) 77
Transthyretin gene mutation (150) 143
Treatment (150) 59

United States (150) 63

Vasomotor reflex (150) 33

Wasting syndrome (150) 153

XK gene (150) 133
XK protein (150) 133
X-linked spinal and bulbar muscular atrophy (150) 161